CMC -- Biopharma’s billion-dollar bottleneck
A strategic blueprint to reduce CMC cycle times by up to 40% and
build a scientist-centered operating model.
THE CMC CONSTRAINT
The science has changed. The operating model has not.
Modern modalities generate levels of scientific, analytical and manufacturing complexity that legacy CMC environments were not designed to support. The result is not one isolated technology problem. It is a breakdown of continuity across data, decisions, samples, processes and teams.
A diagnosis of the constraint and a blueprint for what comes next
The paper connects enterprise impact, scientific evidence,
workflow design, orchestration and technology transfer into one scientist-centered CMC operating model.
Why CMC became the bottleneck
How complexity, organizational silos and fractured technology transfer created the rate-limiting constraint between discovery and launch.
02
The enterprise cost of delay
03
Liberating trapped scientific evidence
04
Rewiring DMTA
Orchestrating the scientist experience
Making technology transfer continuous
Six reinforcing moves for scientist-centered CMC
The model does not depend on a monolithic replacement
programme.
From isolated systems to connected scientific context.
Four propositions that challenge the current CMC operating model
Each proposition reframes a familiar digital or operational problem as a breakdown in scientific continuity.
Scientists are burdened with excessive manual data wrangling
The paper examines how manual cleanup, reconciliation and context reconstruction divert scientific capacity away from process understanding and optimization.
The problem is not simply that data is fragmented.
Digitizing a broken workflow does not create transformation.
It creates a faster version of the same constraint. Operating-model redesign must precede or accompany technology implementation.
Technology transfer should not begin at the point of handoff.
PERSPECTIVE SHAPED IN PRACTICE
A point of view built
across the science-
to-scale journey
Zifo works at the intersection of science, data, informatics and operations across research, development, CMC, manufacturing and quality.
This position paper reflects that cross-lifecycle perspective: where scientific context is lost,
where evidence becomes trapped, where workflows fracture, and what it takes to reconnect
decisions and execution from development through technology transfer.
7 of 15
Leading global biopharma companies use
Zifo’s CMC services
2,500+
190+
READ THE POSITION PAPER
CMC does not have to remain the bottleneck
Explore the operating-model, data and technology
shifts required to create a faster, more connected
and scientist-centered CMC value chain.
Access the Position Paper
Your details will be handled in accordance with Zifo’s Privacy Policy.
CONTINUE THE CONVERSATION
Catalyst by Zifo
A curated practitioner community for senior leaders working across science, data,
informatics, AI and enterprise transformation.
About the
position paper
Who is this position paper intended for?
The paper is intended for senior leaders across CMC, pharmaceutical and process development, analytical development, MSAT, manufacturing, quality, regulatory, scientific informatics, data, AI and digital transformation.
Is the position paper free to access?
Yes. Complete the short form to access the full position paper.